Literature DB >> 1750088

FK 506 used as rescue therapy for human liver allograft recipients.

A J Demetris1, J J Fung, S Todo, J McCauley, A Jain, S Takaya, M Alessiani, K Abu-Elmagd, D H Van Thiel, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1750088      PMCID： PMC3008423     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  3 in total

1.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Pathologic observations in human allograft recipients treated with FK 506.

Authors:  A J Demetris; J J Fung; S Todo; B Banner; T Zerbe; G Sysyn; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321
  3 in total
  4 in total

Review 1.  Liver transplantation in the UK.

Authors:  S R Bramhall; E Minford; B Gunson; J A Buckels
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

3.  Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs.

Authors:  J G Lunz; S Contrucci; K Ruppert; N Murase; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

4.  Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial.

Authors:  D H Van Thiel; H Wright; P Carroll; K Abu-Elmagd; H Rodriguez-Rilo; J McMichael; W Irish; T E Starzl
Journal:  Am J Gastroenterol       Date:  1995-05       Impact factor: 10.864
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.